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Abstract
Background: Non-invasive ventilation (NIV) has been recommended as the best respiratory support for preterm
infants with respiratory distress syndrome (RDS). However, the best NIV technique to be used as first intention in
RDS management has not yet been established.
Nasal intermittent positive pressure ventilation (NIPPV) may be synchronized (SNIPPV) or non-synchronized to the
infant’s breathing efforts.
The aim of the study is to evaluate the short-term effects of SNIPPV vs. NIPPV on the cardiorespiratory events, trying
to identify the best ventilation modality for preterm infants at their first approach to NIV ventilation support.
Methods: An unmasked randomized crossover study with three treatment phases was designed. All newborn
infants < 32 weeks of gestational age with RDS needing NIV ventilation as first intention or after extubation will be
consecutively enrolled in the study and randomized to the NIPPV or SNIPPV arm. After stabilization, enrolled
patients will be alternatively ventilated with two different techniques for two time frames of 4 h each. NIPPV and
SNIPPV will be administered with the same ventilator and the same interface, maintaining continuous assisted
ventilation without patient discomfort.
During the whole duration of the study, the patient’s cardiorespiratory data and data from the ventilator will be
simultaneously recorded using a polygraph connected to a computer.
The primary outcome is the frequency of episodes of oxygen desaturation. Secondary outcomes are the number of
the cardiorespiratory events, FiO2 necessity, newborn pain score evaluation, synchronization index, and
thoracoabdominal asynchrony. The calculated sample size was of 30 patients.
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Discussion: It is known that NIPPV produces a percentage of ineffective acts due to asynchronies between the
ventilator and the infant’s breaths. On the other hand, an ineffective synchronization could increase work of
breathing. Our hypothesis is that an efficient synchronization could reduce the respiratory work and increase the
volume per minute exchanged without interfering with the natural respiratory rhythm of the patient with RDS. The
results of this study will allow us to evaluate the effectiveness of the synchronization, demonstrating whether
SNIPPV is the most effective non-invasive ventilation mode in preterm infants with RDS at their first approach to
NIV ventilation.
Trial registration: ClinicalTrials.gov NCT03289936. Registered on September 21, 2017.
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Background
Respiratory problems are some of the major issues to
deal with in preterm infants [1].
Because of the immaturity of respiratory mechanisms
and structures, the use of support devices is often neces-
sary. These include both conventional mechanical venti-
lation (MV) techniques, which require the use of an
endotracheal tube, as well as non-invasive ventilation
(NIV) techniques that use softer ventilator-patient inter-
faces. Increasing attention is being paid to the latter ones
as they are less aggressive and associated with better
outcomes both in terms of mortality and short and long-
term complications, such as bronchopulmonary dyspla-
sia (BPD) [2, 3].
Nasal intermittent positive pressure ventilation (NIPP
V) is a NIV technique in which the infant’s airways are
kept open between two pressure levels: peak inspiratory
pressure (PIP) and positive end-expiratory pressure
(PEEP) [4, 5]. The frequency and duration of each phase
are defined by setting the inspiratory and expiratory
times or the ventilation rate.
This technique has already shown its superiority in
terms of reduced duration of MV, reduced necessity of
intubation, decreased extubation failure, and reduced
prevalence of BPD if compared with non-invasive tech-
niques based on continuous pressure support, such as
continuous positive airway pressure (CPAP) [6]. Recent
meta-analyses of studies where NIPPV was used as an
alternative to CPAP following extubation show that it
reduces the need for re-ventilation and air leaks, without
reducing BPD [7]. There is insufficient evidence to rec-
ommend NIPPV as the primary mode of respiratory sup-
port in the delivery room [1].
It is important to specify that the ventilation rate on
NIPPV does not reflect the real infant’s spontaneous re-
spiratory rate (RR), as the ventilator supplies the PIP re-
gardless of respiratory efforts. In order to reproduce a
more physiological and gentle ventilation, new devices
have been developed able to detect the infant’s respira-
tory effort and consequently supply a PIP, synchronizing
the ventilation rate with the infant’s RR.
The devices used for synchronization can identify the
infant’s respiratory effort by detecting variation in flow
or pressure. While the MV circuit can detect the exact
beginning of inspiration through the continuous moni-
toring of pressure or through the precise interception of
inspiratory and expiratory flow, some difficulties occur
in NIV where, as a consequence of the impossibility to
detect expiratory flow, the moment of the exact begin-
ning of spontaneous inspiration is hard to identify.
Recently, a new type of NIV ventilator equipped with
a pressure sensor has been put on the market. The soft-
ware of this ventilator is able to calculate the flow ac-
cording to the pressure variations of the circuit and to
capture the flow variations induced by spontaneous
breathing, allowing synchronization of the flow with the
patient’s respiratory acts [8].
The use of a synchronized NIV technique would allow
for a more physiological respiratory support, reducing
respiratory fatigue and improving the infant’s compli-
ance. Despite these premises, the diffusion of synchro-
nized NIPPV (SNIPPV) in neonatal intensive care units
(NICUs) and studies on its efficacy are limited [9].
Some authors have already demonstrated the benefits
of using a synchronized NIV technique in terms of extu-
bation success rate, BPD prevalence, mortality, and neu-
rocognitive development [2, 8]. SNIPPV seems more
effective than NIPPV and nasal CPAP (NCPAP) in redu-
cing the need for intubation in respiratory distress syn-
drome (RDS), in improving the success of extubation,
and in treating apnea of prematurity, with a reassuring
absence of relevant side effects [7, 8, 10]. SNIPPV deliv-
ered through a ventilator can reduce extubation failure
but may not confer long-term advantages such as reduc-
tion in BPD [1]. Other reported beneficial aspects of
SNIPPV include improved thoracoabdominal synchrony,
reduced work of breathing (WOB), and reduced need
for intubation [5, 7, 11].
It has already been shown that SNIPPV is more effect-
ive than NIPPV and NCPAP in reducing the number of
desaturations and apneas in preterm infants undergoing
CPAP treatment for apnea of prematurity [12]. However,
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the effectiveness of SNIPPV compared to NIPPV in pre-
term infants with RDS is still not completely clear.
Our study protocol was designed to evaluate the
short-term effects of SNIPPV vs. NIPPV on the major
cardiorespiratory variables, trying to identify the best
ventilation modality for preterm infants at their first ap-
proach to NIV ventilation support, on the bases of car-




Evaluate the short-term effects of SNIPPV vs. NIPPV in
a group of preterm infants on the cardiorespiratory
events at their first approach to NIV ventilation as first
intention (soon after birth) or after extubation.
Study design and setting
The study has been designed as an unmasked random-
ized crossover study. It will involve the NICU of the
University of Turin. The data analysts will be masked.
Inclusion criteria
All newborn infants with RDS needing NIV ventilation
(NIPPV or SNIPPV) as first intention or after extubation
and with all following characteristics will be consecu-
tively enrolled in the study:
1. Gestational age (GA) at birth < 32 weeks
2. First approach to NIV ventilation (first intention or
after extubation)
3. Parental written consent
4. ≤ 7 days of life
Exclusion criteria
The following are the study exclusion criteria:
1. Neurological (including intraventricular
hemorrhage (IVH) > 2° grade) or surgical diseases
2. Sepsis (clinical or laboratory-confirmed)
3. Chromosomal or genetic abnormalities
4. Major malformations and congenital anomalies
5. Cardiac problems (including hemodynamically
significant patent ductus arteriosus (PDA))
6. Contraindication to NIV (i.e., nasal trauma and
gastrointestinal surgery within the previous 7 days).
Recruitment and randomization
Both parents will sign an informed written consent, and
sufficient time will be allowed for consent. Non-Italian-
speaking parents will only be asked for their consent if
an adult interpreter is available. To support the involve-
ment of participants whose first language is not Italian, a
trusted interpreter and a cultural mediator will be used.
The decision to use a NIV support will be based on
clinical evaluation. For patients enrolled at NICU admis-
sion (first intention subgroup), infants will be enrolled as
soon as possible in their first 24 h of life. For patients en-
rolled after extubation (after extubation subgroup), in-
fants will be enrolled at the moment of extubation. At
the start of NIV, eligible patients will be allocated to one
of the two arms (NIPPV-SNIPPV-NIPPV or SNIPPV-
NIPPV-SNIPPV) by block randomization. Custom soft-
ware will be used to obtain an arbitrary sequence to
randomize patients to both arms, creating balance be-
tween patients needing NIV as first intention or after
extubation.
After 2 h of stabilization (stabilization phase) in the
randomly assigned NIV mode, enrolled patients will be
alternatively ventilated with the two different techniques
for two time frames of 4 h each. If surfactant is needed
before starting the study, the stabilization phase will last
4 h after administration.
Infants will be kept supine throughout the study. During
the whole study duration (including the stabilization
phase), all patients will be continuously monitored with a
multiparametric monitor and the data from the ventilator
will also be recorded. The first hour of each NIPPV/
SNIPPV time frame will be considered as the wash-out
phase and named “adaptation phase”: the data recorded
during this phase will be excluded from the analysis. Milk
meals will be administered during the adaptation phase.
Pain and compliance scales will be filled in by nurses
every 60 min. Blood gas analysis (BGA) values will be re-
corded at the end of the stabilization phase, at the end
of phase A (first NIV modality), and phase B (second
NIV modality).
Patients will drop out of the study in case of:
1. NIV failure criteria: FiO2 > 40%, pH < 7.2, pCO2 >
65mmHg, ≥ 3 episodes of desaturations
(transcutaneous O2 saturation (SatO2 TC) < 80%)
per hour, ≥ 3 episodes of apnea (> 20 s) and/or
bradycardia (heart rate (HR) < 80 beats per minute
(bpm)) per hour, Silverman score > 6. Necrotizing
enterocolitis, bowel perforation, and hemodynamic
instability are indications of NIV failure [13]
2. Air leak syndrome (i.e., pneumothorax)
3. Need for invasive procedures during the study
4. Need for surfactant during the study
5. Development of hemodynamic instability or surgical
problems during the study
6. Death
Data obtained from dropouts (patients who drop out
of the study) will be analyzed separately.
After 8 h of study (and 2 h of stabilization phase), each
patient will be ventilated with the best NIV modality
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according to clinical data and the cardiorespiratory pa-
rameters observed during the study.
The design of the study is outlined in Fig. 1.
Techniques
NIV ventilator
NIPPV is a non-invasive ventilation technique in which
PIP administration is not synchronized with the infant’s
respiratory efforts. SNIPPV is a non-invasive ventilation
technique in which PIP administration is synchronized
with the infant’s respiratory efforts.
NIPPV and SNIPPV will be delivered using a Giulia® neo-
natal ventilator via nasal prongs (Ginevri Medical Tech-
nologies, Rome, Italy). With this device, clinicians can
switch from NIPPV to SNIPPV mode and vice versa with-
out changing the circuit and the ventilation interface avoid-
ing discomfort for the patient. The size of the nasal prongs
will be determined by the infant’s weight and characteristics
to minimize nasal air leaks as per the manufacturer’s rec-
ommendation. In SNIPPV mode, the synchronization will
be achieved through an algorithm based on flow detection
through a fixed orifice pneumotachograph (2.5mm inner
diameter—dead space 1mL) interposed between the prongs
and the Y piece (flow-SNIPPV).
The optimal NIV setup will be decided by the clini-
cians and individualized for each patient during the
stabilization phase in order to obtain the lowest FiO2
levels necessary to reach SatO2 TC of 90–94% then the
values of PEEP, PIP, backup RR, flow, and inspiratory
time will be kept constant during phases A and B.
Polygraphy
The Embletta® MPR PG (PG (Multi Parameter Recorder
- Polygraphy) - XS is a multiparametric polygraph that
Fig. 1 Study design
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records the patient’s ECG trace (to calculate HR), FiO2,
pulse-oximeter (to obtain HR and SatO2 TC), respiratory
curve (thoracic impedance, through which RR is calcu-
lated). The Embletta® will also be interfaced with Giulia®
ventilator using a custom interface (Ginevri Medical
Technologies, Rome, Italy) that will obtain three analog
output channels (trigger, pressure, flow) from the Giulia®
ventilator.
Data from Embletta® will be analyzed by a designed
software provided by the manufacturer.
Monitoring and data collection
Data on respiratory support and overall clinical status
will be collected from enrolment to discharge. Data will
be recorded continuously by the polygraph from enrol-
ment to the end of the study.
All the data that will be collected will be obtained
from the clinical records and from the Embletta® MPR
PG-XS. Data will be recorded on a database specifically
designed for this study. Access to the database will be
password protected. Participants will be identified by
trial number only.
Data obtained from the clinical records cannot be
modified after being recorded in the database. Data from
the Embletta® MPR PG-XS will be recorded and ana-
lyzed by software provided by the manufacturer and can-
not be modified.
All data recorded throughout the study period are
listed in Table 1.
Cardiorespiratory events
Cardiorespiratory events are defined as episodes of apnea
lasting more than 20 s or over 5 s if followed by desatur-
ation or bradycardia and/or episodes of desaturation in
which blood oxygen saturation falls below 80% for 4 s
or more and/or episodes of bradycardia with HR
below 80 bpm.
Outcomes
The primary outcome of the study is the frequency of
episodes of desaturation.
Secondary outcomes are listed below:
1. The number of the cardiorespiratory events (apnea,
bradycardia, oxygen desaturation)
2. FiO2 needing during SNIPPV vs. NIPPV monitoring
to maintain SatO2 TC between 90 and 94%, defined
as mean fraction of inspired oxygen, expressed in
percentage
3. Newborn pain score evaluation during SNIPPV vs.
NIPPV monitoring, using Neonatal Pain Scale Score
4. Synchronization index, defined as the percentage of
spontaneous breaths supported by the ventilator
5. Patient-ventilator concordance, defined as the time
between the onset of the patient’s inspiratory effort
and mechanical inflation in synchronized
ventilation
6. Thoracoabdominal asynchrony, defined as the
phase difference between thoracic and abdominal
impedance
Dropout patients will be considered to establish the
frequency of NIV failure, NIV weaning, and the need for
surfactant during each phase of the study.
The main result will be the difference in cardiorespira-
tory events during SNIPPV versus NIPPV.
Tolerance to each of the two NIV modalities will be
evaluated by evaluating the number of failure episodes
Table 1 Data recorded before and during the study period
Before enrolment During the study period
ANAMNESTIC VARIABLES
- GA at birth
- Birth weight
- Delivery type
- APGAR at 1/5 min (and 10 min if available)
- Presence of intrauterine growth restriction
- Maternal administration of magnesium sulfate
- Steroid prenatal prophylaxis (number of doses)
- Intrapartum antibiotic prophylaxis (if indicated)
- Presence of intraamniotic infection and administration of
intrapartum antibiotic therapy
CLINICAL VARIABLES
- Surfactant administration (time and number of doses)
- Type and duration of MV previously administered (if any)
- Type and duration of NIV previously administered (if any)
- Corrected GA at enrolling
- Caffeine doses administered (if any)
CARDIORESPIRATORY VARIABLES
- FiO2 to maintain SatO2TC 90-94% (as weighted mean)
- NIV failurea and endotracheal intubation
- Number of the cardiorespiratory eventsb





- from ventilator: trigger, pressure, flow
- pressure in ventilator circuit
CLINICAL VARIABLES
- Neonatal Pain Scale score
LABORATORY VARIABLES
- BGA values at the end of stabilization phase, phase A and phase B
GA gestational age, MV mechanical ventilation, NIV non-invasive ventilation, SatO2 TC transcutaneous O2 saturation, HR heart rate, RR respiratory rate
aNIV failure criteria: FiO2 > 40%, pH < 7.2, pCO2 > 65 mmHg, ≥ 3 episodes of desaturations (SatO2 TC < 80%) per hour, ≥ 3 episodes of apnea (> 20 s) and/or
bradycardia (HR < 80 bpm) per hour, Silverman score > 6. Necrotizing enterocolitis, bowel perforation, and hemodynamic instability are indications of NIV failure
bCardiorespiratory events are defined as episodes of apnea lasting more than 20 s or over 5 s if followed by desaturation or bradycardia and/or episodes of
desaturation with blood oxygen saturation below 80% for 4 s or more and/or episodes of bradycardia with HR below 80 bpm.
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and the cardiorespiratory events and analyzing the
scores for individual compliance and pain. The individ-
ual need for oxygen under the two NIV modalities will
be considered a known risk factor for premature retin-
opathy and various other complications.
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) figure of enrolment, inter-
ventions, and assessments is shown in Fig. 2. The SPIR
IT checklist is provided as Additional file 1.
Statistical analysis and sample size
Descriptive variables will be analyzed in function of their
distribution. T student test or Mann Whitney U test in
case of continuous variables (if normally or not normally
distributed respectively) and chi-squared or fisher test
for qualitative ones. All tests will be two-sided with a
significance threshold of 0.05.
A subgroup analysis will be performed according to
the time of NIV support (first intention or after
extubation).
The number of patients to be enrolled is calculated
considering clinically relevant a difference of 30% in car-
diorespiratory events between the two ventilation modal-
ities. Assuming a mean of 5 and a SD of 1.5 events/h
(based on available literature data), the number of pa-
tients to be enrolled is 30, to obtain an 80% power and a
significance threshold of 0.05.
Quality control and quality assurance procedures
Compliance to protocol
Compliance will be defined as full adherence to protocol.
Compliance with the protocol will be ensured by a num-
ber of procedures as described.
Site setup
Principal investigators will participate in preparatory
meetings in which details on study protocol, non-
invasive ventilation, multiparametric polygraph, and data
collection will be accurately discussed with all NICU
staff, including nursing and medical staff.
Fig. 2 Spirit figure
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Safety
Safety endpoints will include incidence, severity, and caus-
ality of reported significant adverse events (SAEs). All
SAEs will be followed until satisfactory resolution or until
the investigator responsible for the care of the participant
deems the event to be chronic or the patient to be stable.
All expected and unexpected SAEs, whether or not they
are attributable to the study intervention, will be reviewed
by the principal investigators to determine if there is a rea-
sonable suspected causal relationship with the interven-
tion. If the relationship is reasonable, SAEs will be
reported to the ethics committee and inform all other in-
vestigators to guarantee the safety of the participants.
Discussion
The European Consensus Guidelines on the Management
of Respiratory Distress Syndrome recommend NIV as the
best respiratory support for preterm infants with RDS [1].
It is well known that the NIV is a valid tool to reduce
the duration and the need for MV. The reduction in MV
is closely related to the development of ventilator lung
injury and complications such as BPD. Early switching
from the MV to the NIV has been advocated, even for
extremely preterm infants [14]. Therefore, it is desirable
to identify the best type of NIV to be used at birth or
after extubation.
The popularity of NIPPV is rising since its comparison
to NCPAP has demonstrated a significant decrease in re-
spiratory failure, re-intubation rates, and extubation fail-
ure [6]. However, there is insufficient evidence to
recommend NIPPV as the primary mode of respiratory
support in the delivery room [1].
Synchronization may be important in delivering effect-
ive NIPPV: studies using SNIPPV and delivering NIPPV
to infants by a ventilator observed benefits more consist-
ently [7].
The periodic breaths of NIPPV increase tidal volume
leading to enhanced removal of CO2, sustained alveolar
ventilation during episodes of apnea and increased func-
tional residual capacity (FRC) [4, 15]. Asynchronies
between ventilator and infant breaths may alter spontan-
eous breath rhythm, induce glottal narrowing, increase
WOB, increase abdominal distension, and cause volu-
trauma. SNIPPV seems to be associated with an increase
in tidal and minute volumes compared to NCPAP [16].
It has also been demonstrated that SNIPPV recruits col-
lapsed alveoli, thereby increasing FRC and decreasing
the need for MV [17]. Several explanations may account
for the effectiveness of SNIPPV: decreased thoracoab-
dominal motion asynchrony and flow resistance through
the nasal prongs, with improved stability of the chest
wall and pulmonary mechanics, increased flow delivery
in the upper airway with the addition of a PIP above
PEEP [18].
Synchronization during nasal ventilation is considered
to provide more efficient respiratory support and syn-
chrony. One of the first studies to demonstrate WOB re-
duction in preterm infants using SNIPPV was conducted
more than ten years ago [19]. Huang et al. [20] sup-
ported these benefits of synchronized ventilation
achieved by using a Graseby capsule, showing an im-
proved gas exchange and a decreased respiratory effort.
Compared to NCPAP and NIPPV, SNIPPV is more ef-
fective in reducing desaturation and apneas; compared
to NCPAP, SNIPPV reduces BPD risk, extubation fail-
ure, and severe retinopathy of prematurity [16, 21].
Gizzi et al. compared the effects of flow-SNIPPV,
NIPPV, and NCPAP on the rates of desaturation and
bradycardias in preterm infants with apnoeic-spells (the
mean GA at study was 30 weeks) [12]. A randomized
crossover study with three treatment phases was con-
ducted: patients received the three modes of ventilation
for 4 h each, using a conventional nasal ventilator able to
provide synchronization by a pneumotachograph (Giu-
lia® ventilator; GINEVRI srl, Albano Laziale, Rome,
Italy). Flow-SNIPPV has been shown to reduce desatur-
ation and apneas in NCPAP infants [12].
SNIPPV may be superior to NIPPV even in patients
with RDS, as first intention (soon after birth) or after
extubation.
As first intention, flow-SNIPPV combined with surfac-
tant seemed to be a promising strategy for treating infants
in the acute phase of RDS [22]. However, a recent meta-
analysis showed that early NIPPV appears to be superior
to NCPAP alone in decreasing respiratory failure and the
need for intubation, without any additional benefits of
SNIPPV [10]. Recently, Handoka et al. reported grade of
RDS, mean airway pressure, and antenatal steroid use as
the predictors of early SNIPPV failure [18].
A lower WOB is an important consideration when
choosing which non-invasive mode should be used to
support preterm infants immediately after extubation.
SNIPPV and NIPPV delivered by a ventilator demon-
strated short-term benefits for extubation failure and
long-term pulmonary effects for BPD and pulmonary air
leaks [7]. SNIPPV post-extubation reduced the WOB
and thoracoabdominal asynchrony [5, 11].
Several fans are currently available for SNIPPV. The
Giulia® ventilator (GINEVRI srl, Albano Laziale, Rome,
Italy) is one of them, providing a flow-SNIPPV. The
Giulia® uses a pressure sensor. The trigger quality of this
system is not known.
It is known that NIPPV produces a percentage of inef-
fective acts because they are not synchronized with pa-
tient’s acts. On the other hand, a bad synchronization
system could have the effect of increasing respiratory
work. Our hypothesis is that a valid synchronization
could reduce the respiratory work and increase the
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volume per minute exchanged without interfering with
the natural respiratory rhythm of the infant with RDS. A
randomized crossover study with three treatment phases
will be conducted to evaluate the short-term effects of
SNIPPV vs. NIPPV in a group of preterm infants at their
first approach to NIV ventilation as first intention or
after extubation on the cardiorespiratory events.
The results of this study will allow us to evaluate the
effectiveness of the synchronization obtained by the
flow-SNIPPV.
The results of this study will demonstrate whether
synchronization is the most effective ventilation mode
even in preterm infants with RDS.
We want to make a few considerations given the popu-
lation for this trial is infants with RDS and the current glo-
bal pandemic of a virus that is especially harmful to
pulmonary systems. Since patients of this trial are preterm
infants admitted in NICU, existing hygiene rules and stan-
dards of care are applied to all patients. Hospital restric-
tions have a significantly limited parental presence for
NICU admitted infants. Otherwise, the trial is not
modified. To accommodate risks and restrictions due
to COVID-19, all neonates born to mothers with sus-
pected or confirmed COVID-19 who need intensive
care are admitted to another unit and are not en-
rolled in the trial.
Trial status
The protocol is syncNIPPV17 version no. 1.6. The re-
cruitment is expected to begin on September 1st, 2020.
The anticipated date of recruitment completion is Au-
gust 31st 2021.
The trial was registered in ClinicalTrials.gov on 09/21/
2017, NCT03289936.
All items from the WHO Trial Registration Data set
can be found within the manuscript.
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